Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Telomir Pharmaceuticals, Inc. - Common Stock (NQ:TELO)

2.485 -0.025 (-1.00%)
Streaming Delayed Price Updated: 12:27 PM EDT, May 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals Lead Drug Candidate Inhibits Tumor Growth In Aggressive Prostate Cancer Cells, Animal Study Shows
Telomir-1 shows potential in oncology and age-related diseases, with new findings on its role in tumor suppression and chemotherapy toxicity reduction. 
Via Benzinga
Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration
Telomir Pharmaceuticals' Telomir-1 stabilizes Silver(II) for medical use, addressing instability issues in antimicrobial treatments and wound care solutions. 
Via Benzinga
EXCLUSIVE: Telomir Pharmaceuticals Reports Potential Of Telomir-1 For Wilson's Disease
Telomir-1 shows potential as a treatment for Wilson's disease and related disorders, with promising preclinical results and potential for orphan drug designation. 
Via Benzinga
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation
Telomir Pharmaceuticals Secures $1 Million At $7 Per Share In No-Warrant, Restricted Stock Deal, Underscoring Investor Confidence With A 20% Premium Valuation 
Via News Direct
Why Is Telomir Pharmaceuticals Stock Trading Higher On Tuesday?
Telomir Pharmaceuticals unveils preclinical data on Telomir-1, highlighting its potential in Type 2 diabetes, aging, and inflammatory diseases. 
Via Benzinga
Turning Back The Clock On Aging: Telomir Pharmaceuticals Confirms Telomir-1 Reverses Age And Increased Longevity In Breakthrough Pre-Clinical Study
Turning Back The Clock On Aging: Telomir Pharmaceuticals Confirms Telomir-1 Reverses Age And Increased Longevity In Breakthrough Pre-Clinical Study 
Via News Direct
Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs
Telomir Pharmaceuticals (NASDAQ: TELO) Featured In Local ABC Exclusive Showing Positive Outcomes Of Proposed Age Reversal Pill In Dogs 
Via News Direct
Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q2 2024
Telomir Pharmaceuticals just reported results for the second quarter of 2024. 
Via InvestorPlace
From Pets To Humans, Telomir Pharmaceuticals (NASDAQ: TELO) Holds The Key To Extending Life, Reversing Aging
From Pets To Humans, Telomir Pharmaceuticals (NASDAQ: TELO) Holds The Key To Extending Life, Reversing Aging 
Via News Direct
TELO Stock Earnings: Telomir Pharmaceuticals Reported Results for Q1 2024
Telomir Pharmaceuticals just reported results for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Why AppLovin Shares Are Trading Higher By Around 22%; Here Are 20 Stocks Moving Premarket
Shares of AppLovin Corporation (NASDAQ: APP) rose sharply in today’s pre-market trading after the company reported better-than-expected fourth-quarter financial 
Via Benzinga
Why Herbalife Shares Are Trading Lower By Around 36%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Herbalife Ltd. (NYSE: HLF) fell sharply in today’s session following weak quarterly earnings. 
Via Benzinga
Cisco Issues Weak Outlook, Joins Fastly, Herbalife And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures trading higher by around 70 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Gilead-Backed Kyverna Overshoots Raised IPO Expectations
Kyverna Therapeutics raised almost $320 million in its initial public offering, which was priced above the marketed range. Backed by Gilead Sciences, the company's offering was the second largest for a... 
Via Talk Markets
Topics Initial Public Offering
Exposures Securities Market
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.